DaVita Inc. (DVA) AI Stock Analysis

DaVita Inc. specializes in kidney dialysis services for patients with chronic kidney failure, offering outpatient, hospital inpatient, and home-based hemodialysis care. The company operates clinical laboratories for end-stage renal disease testing and provides vascular access services, physician care, and integrated disease management programs. Domestically, DaVita operates 2,815 outpatient dialysis centers serving approximately 203,100 patients as of December 31, 2021, while delivering acute inpatient dialysis across roughly 850 hospitals nationwide. Globally, it runs 339 outpatient dialysis centers across 10 countries, catering to around 39,900 patients.

Between FY2021 and FY2025, DaVita expanded annual revenue from $11.62B to $13.64B, achieving a 5-year revenue CAGR of 3.4%. Net income fluctuated over this span, moving from $978.5M in FY2021 down to $560.4M in FY2022, before reaching $746.8M in FY2025 with an operating margin of 14.7%. Despite bottom-line volatility, EPS rose from $9.11 in FY2021 to $10.86 in FY2025. In the trailing twelve months ended June 30, 2026, revenue totaled $14.01B with an operating margin of 16.1%. For the latest quarter, quarterly revenue grew 5.2% year-over-year while quarterly earnings expanded by 55.8%.

As of June 30, 2026, DaVita held $688.9M in cash and short-term investments against $10.78B in total debt, leading to net debt of $10.09B and negative shareholders' equity of -$765.1M. The company reported total assets of $17.71B and a current ratio of 1.47. In FY2025, operating cash flow reached $1.89B and free cash flow was $1.31B. Capital expenditures consumed $575.9M, while $1.79B went to share buybacks, contributing to a 37.0% reduction in share count over 5 years.

DaVita trades at a trailing P/E of 15.8x and a forward P/E of 10.0x, both sitting below the median of its S&P 500 Healthcare peers at 28.9x and 16.6x, respectively. The company's EV to EBITDA stands at 8.8x compared to the peer median of 15.7x, while its price-to-sales multiple is 0.9x versus the peer median of 3.4x. Over the past year, the stock gained 49.5%, outperforming the S&P 500 benchmark return of 16.8%. Over a 5-year timeframe, the stock gained 66.9%, trailing the benchmark return of 83.0%.

Wall Street analyst ratings consist of 3 Strong Buy, 4 Hold, and 1 Sell. The mean price target is $219.86, representing a 17.4% upside relative to the last close of $187.31. For the fiscal year ending December 31, 2026, consensus expectations project revenue of $14.16B and EPS of $14.82, representing 37.5% earnings growth. For the following fiscal year, 8 analysts estimate revenue of $14.64B and EPS of $17.14. DaVita has beaten EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for November 4, 2026.

This page is an AI-written research summary of DaVita Inc. (DVA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DVA income statement, DVA balance sheet, DVA key metrics, DVA analyst forecast, DVA chart. See the DVA stock overview for the latest quote and news.